Abstract: The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT- containing dosage units and other compositions.
Type:
Application
Filed:
July 18, 2019
Publication date:
August 5, 2021
Applicants:
WisTa Laboratories Ltd., Charles Robert Harrington
Inventors:
Claude Michel Wischik, Bjorn Olaf Schelter, Flelen Christine Shiells